UNSPSC 51161566: Cromitrile sodium

This classification denotes an anti-asthmatic agent with the molecular formula C20H14N5O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z9FYZ8P9ND, chemically known as benzonitrile, 4-(2-hydroxy-3-((4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-5-yl)oxy)propoxy)-,monosodium salt but more generally known as cromitrile sodium, which bears US NIH Compound Identifier 40856. Most nations, for tariff and trade purposes, schedule cromitrile sodium under HS 29349990 and SITC 51579.

As of Q4 2014, CROMITRILE SODIUM remains US FDA's Preferred Term for this commodity. Cromitrile sodium bears US NLM identifiers UMLS ID C2825630 and NCI Concept Code C81438. SMILES: C1CC2C(C(C1)OCC(COC3CCC(CC3)C#N)O)C(=O)CC(O2)C4[N-]NNN4.[NA+].

UNSPSC 51161566 Cromitrile sodium is a Commodity code covering pharmaceutical ingredients and finished drug products supplied through state and local cooperative purchasing frameworks. State and local governments buy pharmaceutical products—both generic multi-source drugs and over-the-counter items—through centralized cooperative agreements that establish pricing and supply relationships with authorized wholesalers serving hospitals, clinics, correctional facilities, and other public health and human services entities. The issuing bodies include state procurement offices and multistate cooperative purchasing alliances administering consolidated pharmaceutical contracts on behalf of member states and subordinate agencies.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local government facilities, including Oregon. The RFP, posted January 20, 2026, with responses due March 26, 2026, seeks manufacturers to supply identified pharmaceutical products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must provide detailed product information including NDC codes, SKUs, UPCs, and manufacturing locations; certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act; maintain relationships with at least two of the three authorized wholesalers; and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures. The evaluation emphasizes price competitiveness (75 percent weight) and administrative compliance, with products required to be available by May 15, 2026, and resulting agreements effective July 1, 2026. The contract term is two years for new vendors with optional extensions, or alignment with existing expiration dates through June 30, 2028, for incumbent responders.